Percheron Therapeutics Ltd
ASX:PER
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.052
0.135
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PER stock under the Base Case scenario is 0.067 AUD. Compared to the current market price of 0.074 AUD, Percheron Therapeutics Ltd is Overvalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Percheron Therapeutics Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PER cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Percheron Therapeutics Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Percheron Therapeutics Ltd
Balance Sheet Decomposition
Percheron Therapeutics Ltd
Current Assets | 14.5m |
Cash & Short-Term Investments | 11.9m |
Receivables | 2.6m |
Other Current Assets | 38.3k |
Non-Current Assets | 56.9k |
PP&E | 56.9k |
Current Liabilities | 5.2m |
Accounts Payable | 3.7m |
Accrued Liabilities | 1.1m |
Other Current Liabilities | 286.2k |
Non-Current Liabilities | 15.2k |
Other Non-Current Liabilities | 15.2k |
Earnings Waterfall
Percheron Therapeutics Ltd
Revenue
|
615.5k
AUD
|
Operating Expenses
|
-14.9m
AUD
|
Operating Income
|
-14.3m
AUD
|
Other Expenses
|
2.3m
AUD
|
Net Income
|
-11.9m
AUD
|
Free Cash Flow Analysis
Percheron Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
PER Profitability Score
Profitability Due Diligence
Percheron Therapeutics Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Percheron Therapeutics Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
PER Solvency Score
Solvency Due Diligence
Percheron Therapeutics Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Percheron Therapeutics Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PER Price Targets Summary
Percheron Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for PER is 0.218 AUD with a low forecast of 0.152 AUD and a high forecast of 0.263 AUD.
Dividends
Current shareholder yield for PER is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
Contact
IPO
Employees
Officers
The intrinsic value of one PER stock under the Base Case scenario is 0.067 AUD.
Compared to the current market price of 0.074 AUD, Percheron Therapeutics Ltd is Overvalued by 9%.